NICE (UK) recommends Piqray + fulvestrant for the treatment of postmenopausal women, and men, with HR+ and HER2-, locally advanced or metastatic breast cancer with a PIK3CA mutation.
Novartis Pharmaceuticals UK announces that the National Institute for Health and Care Excellence (NICE) has recommended the use of Piqray (alpelisib) for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy.
Resistance to endocrine therapy is a significant concern in the treatment of advanced breast cancer. PIK3CA mutations are a driver of developing endocrine resistance, which may lead to faster disease progression for patients, and a worse prognosis. Endocrine resistance affects approximately 40% of HR+/HER2- advanced breast cancer patients. There is a need for new therapies like alpelisib that are able to specifically target the PIK3CA mutation, with the goal of improved efficacy with a manageable toxicity profile that may maintain quality of life.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.